Lurbinectedin is an antineoplastic agent categorized as a tetrahydroisoquinoline alkaloid, primarily indicated for the treatment of metastatic small cell lung cancer in adult patients. As a potent alkylating… Read more




























Lurbinectedin is an antineoplastic agent categorized as a tetrahydroisoquinoline alkaloid, primarily indicated for the treatment of metastatic small cell lung cancer in adult patients. As a potent alkylating agent that binds to the minor groove of DNA, this molecule requires rigorous analysis throughout pharmaceutical development. This category contains a comprehensive selection of high-quality reference standards, including the parent drug, its known process-related impurities, degradation products, and specific metabolites such as M4. Laboratories utilize these compounds for precise impurity profiling and the development of robust analytical methods. Furthermore, the inclusion of stable isotope labelled standards is essential for accurate quantification in complex biological matrices via mass spectrometry, ensuring rigorous quality control and compliance with regulatory standards throughout the drug’s lifecycle.